London, United Kingdom: Insomnia patients who consume cannabis products report sustained improvements in their sleep quality, according to data published in the journal Brain & Behavior.
British investigators assessed the safety and efficacy of plant-derived cannabis products (either oils, flower, or a combination of both) in over 60 patients enrolled in the UK Medical Cannabis Registry. Cohort participants possessed a doctor’s authorization to access cannabis products. (Since 2018, specialists have been permitted to prescribe cannabis-based medicinal products to patients unresponsive to conventional medications.) Authors assessed the efficacy of cannabis at one, three, and six months.
Researchers reported that cannabis products were “well tolerated” and that they were associated with better sleep, reduced anxiety, and greater quality of life.
They concluded: “More than 40 percent of participants who completed each PROM [patient-reported outcome measure] round reported clinically significant improvement in their sleep quality at each time period. These results show that initiation of CBMP [cannabis-based medicinal products] therapy was associated with improvements in those patients who had previously failed to respond to currently licensed treatments for insomnia.”
Other studies assessing the use of cannabis products in patients enrolled in the UK Cannabis Registry have reported them to be effective for those suffering from chronic pain, anxiety, post-traumatic stress, depression, migraine, inflammatory bowel disease, and other afflictions.
Placebo-controlled clinical trial data has previously affirmed the efficacy of plant-derived cannabis extracts in patients suffering from chronic insomnia.
Full text of the study, “UK Medical Cannabis Registry: Assessment of clinical outcomes in patients with insomnia,” appears inBrain & Behavior.Additional information on cannabis and insomnia is available from NORML’s publication, Clinical Applications for Cannabis & Cannabinoids.